14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
FRSX vs EVGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Evogene Ltd. (EVGN) is the stronger overall head-to-head candidate over Foresight Autonomous Holdings Ltd. (FRSX) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). FRSX carries a Unified Composite Score of 40.4/100 (SELL) at $0.47 (N/M Forward P/E, -2642.2% operating margin), whereas EVGN carries 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin).
Growth vs. Quality Trade-Off: EVGN earns the overall head-to-head edge with a stronger Unified Composite Score (44.1/100 HOLD vs. FRSX 40.4/100 SELL) and 1.37β · 138% Vol risk profile, whereas FRSX leads top-line expansion (-32.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: FRSX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.4); meanwhile EVGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FRSX vs EVGN. Trailing 12-month operating profitability (FRSX -2642.2% vs EVGN -858.2%) and valuation multiples (FRSX N/M vs EVGN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $6.0M market capitalization and -858.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ FRSX vs EVGN Key Questions & Quantitative Answers
As of Nov 17, 2026, Evogene Ltd. (EVGN) is the stronger overall head-to-head candidate over Foresight Autonomous Holdings Ltd. (FRSX) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). FRSX carries a Unified Composite Score of 40.4/100 (SELL) at $0.47 (N/M Forward P/E, -2642.2% operating margin), whereas EVGN carries 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin). Growth vs. Quality Trade-Off: EVGN earns the overall head-to-head edge with a stronger Unified Composite Score (44.1/100 HOLD vs. FRSX 40.4/100 SELL) and 1.37β · 138% Vol risk profile, whereas FRSX leads top-line expansion (-32.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: FRSX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.4); meanwhile EVGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FRSX leads the Growth & Scale pillar: FRSX posts -32.8% YoY revenue growth and +0.0% YoY earnings growth on $445,000 TTM revenue (65.4% gross margin, -2642.2% operating margin), compared with EVGN at -60.7% YoY revenue growth and +0.0% YoY earnings growth on $1.7M TTM revenue (-67.6% gross margin, -858.2% operating margin). On trailing 12-month operating scale, FRSX generates $445,000 in USD-normalized revenue versus $1.7M for EVGN. In operating R&D and SG&A reinvestment, FRSX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVGN.
FRSX screens cheaper on headline valuation multiples. FRSX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.5x EV/Revenue (unreported EBITDA margin), whereas EVGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FRSX (-205.9% ROE) versus EVGN (-182.8% ROE) capital efficiency.
In options market volatility and institutional positioning, FRSX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 57% Vol realized risk). By comparison, EVGN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.37β · 138% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.